Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland:

摘要

Objective:Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir.Methods:Retrospective health care record of 61 consecutive HIV treatment-naive patients started on dolutegravir was reviewed and analysed on SPSS.Results:The mean initial viral load was 160826.05?copies/mL (range, 79–1,126,617?copies/mL). HIV viral load became non-detectable in 63.9% of patients on dolutegravir within 3?months. In all, 60.7% of patients reported no side effects on dolutegravir; 98.4% of the patients claimed full compliance to their antiretrovirals.Conclusion:Dolutegravir was found to be efficacious and well tolerated in HIV-infected treatment-naive patients.